adjuvantadvancedalgorithmaskedbenefitbestbiologybladdercancercarcinomacarecasecellcisplatinclinicalcurrentdecisiondiseasedrivenexchangeexpertfaqsfirstfrequentlyg12cimmunotherapyineligibleinsightsinterviewinvasivekraslinelocallymaintenancemakingmanagementmaximizingmetastaticmibcmolecularmusclemutationsnmibcnsclconcogeneoptimaloptimizationosimertinibpatientspracticequestionsreconsideringrenalresistancesalvagescchnsclcsecondsequentialsessionspecialiststandardstrategiesstrategysurvivaltargetingtherapytreatmenttreatmentsucunresectableupdatesurothelialvienna